Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

BioStock Studio: Spago Nanomedical's CDO on the endometriosis study

Spago Nanomedical

First North-listed Spago Nanomedical has recently initiated a phase IIa study with the MRI contrast agent SpagoPix in endometriosis. Paul Hargreaves, Chief Development Officer, visited BioStock's studio and talked about the disease, the need for better diagnostics and the phase IIa study.

Watch the interview with Spago Nanomedical's CDO Paul Hargreaves at biostock.se:

https://www.biostock.se/en/2022/12/spago-nanomedicals-cdo-on-the-endometriosis-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.